

Daftar Pustaka

- Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., DeFazio, A., Bowtell, D., & Brenton, J. D. (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *Journal of Pathology*, *221*(1), 49–56.
<https://doi.org/10.1002/path.2696>
- Anonim. (n.d.-a). *Cell Biology*. <https://www.genome.gov/genetics-glossary/>
- Anonim. (n.d.-b). *tRNA*.
<http://biology.kenyon.edu/courses/biol114/Chap05/Chapter05.html>
- Anonim. (2015). *Cancer Facts & Figures 2015*.
- Anonim. (2019). *Cancer Stat Facts: Ovarian Cancer*. National Cancer Institute, Surveillance, Epidemiology, and End Results Program.
<https://seer.cancer.gov/statfacts/html/ovary.html>
- Arjmand, M., & Avval, F. Z. (2019). *Clinical biomarkers for detection of ovarian cancer*. *2*(1), 3–7.
- Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynecology and Obstetrics*, *143*, 59–78. <https://doi.org/10.1002/ijgo.12614>
- Bilalović, N., Vranić, S., Hasanagić, S., Basić, H., Tatarević, A., Beslija, S., & Selak, I. (2004). The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. *Bosnian Journal of Basic Medical Sciences / Udruzenje Basicnih Mediciniskih Znanosti = Association of Basic Medical Sciences*, *4*(4), 5–12. <https://doi.org/10.17305/bjbms.2004.3352>
- Borner, C. (2003). The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. *Molecular Immunology*, *39*, 615–647.
- Budiana, I. (2013). *ASSOCIATION OF B-CELL LYMPHOMA PROTEIN-2 AND CASPASE-3 EXPRESSION IN OVARIAN CANCER*. *2*, 67–73.

- Bulun, S. E. (2009). Mechanism of Disease Endometriosis. *The New England Journal of Medicine*, (360), 268–279.
- Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *Journal of Clinical Oncology*, 25(25), 3985–3990. <https://doi.org/10.1200/JCO.2007.12.2622>
- Carcangiu, M. L., Radice, P., Manoukian, S., Spatti, G., Gobbo, M., Pensotti, V., Crucianelli, R., & Pasini, B. (2004). Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers. *International Journal of Gynecological Pathology*, 23(1), 35–40. <https://doi.org/10.1097/01.pgp.0000101082.35393.84>
- Chan, J. K., Teoh, D., Hu, J. M., Shin, J. Y., Osann, K., & Kapp, D. S. (2008). Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. *Gynecologic Oncology*, 109(3), 370–376. <https://doi.org/10.1016/j.ygyno.2008.02.006>
- Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016). Cancer statistics in China, 2015. *CA: A Cancer Journal for Clinicians*, 66(2), 115–132. <https://doi.org/10.3322/caac.21338>
- Cheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005). Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. *Nature Medicine*, 11(5), 531–537. <https://doi.org/10.1038/nm1230>
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. *Science*, 265(5170), 346–355. <https://doi.org/10.1126/science.8023157>
- Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., Nur,

- U., Tracey, E., Coory, M., Hatcher, J., McGahan, C. E., Turner, D., Marrett, L., Gjerstorff, M. L., Johannesen, T. B., Adolfsson, J., Lambe, M., Lawrence, G., Meechan, D., ... Richards, M. A. (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the international cancer benchmarking partnership): An analysis of population-based cancer registry data. *The Lancet*, 377(9760), 127–138.
[https://doi.org/10.1016/S0140-6736\(10\)62231-3](https://doi.org/10.1016/S0140-6736(10)62231-3)
- Colgan, T. J., Murphy, J., Cole, D. E. C., Narod, S., & Rosen, B. (2001). Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. *American Journal of Surgical Pathology*, 25(10), 1283–1289. <https://doi.org/10.1097/00000478-200110000-00009>
- Cory, S., & Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. *Cancer*, 2, 647–656.
- Cory, S., Huang, D. C., & Adams, J. M. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. *Oncogene*, 22, 8590–8607.
- Coticchia, C. M., Yang, J., & Moses, M. A. (2008). Ovarian cancer biomarkers: Current options and future promise. *JNCCN Journal of the National Comprehensive Cancer Network*, 6(8), 795–802.
<https://doi.org/10.6004/jnccn.2008.0059>
- Deligdisch, L., Gil, J., Kerner, H., Wu, H. S., Ph, D., Beck, D., & Gershoni-baruch, R. (1999). *Ovarian Dysplasia in Prophylactic Oophorectomy Specimens Cytogenetic and Morphometric Correlations*. 1544–1550.
- Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., Feng, J., & Chen, X. (2017). Age is associated with prognosis in serous ovarian carcinoma. *Journal of Ovarian Research*, 10(1), 1–9. <https://doi.org/10.1186/s13048-017-0331-6>
- Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nuñez, G., & Castle, V. P. (1995). Bcl-xL Is Expressed in Neuroblastoma Cells and Modulates

- Chemotherapy-induced Apoptosis. *Cancer Research*, 55(12), 2576–2582.
- Dubeau, L. (2008). THE CELL OF ORIGIN OF OVARIAN EPITHELIAL TUMORS. *Lancet Oncology*, 9(12), 1191–1197.
- Fan, T. J., Han, L. H., Cong, R. S., & Liang, J. (2005). Caspase family proteases and apoptosis. *Acta Biochimica et Biophysica Sinica*, 37(11), 719–727.
<https://doi.org/10.1111/j.1745-7270.2005.00108.x>
- Fauvet, R., Dufournet, C., Poncelet, C., Uzan, C., Hugol, D., & Daraï, E. (2005). Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. *Journal of Surgical Oncology*, 92(4), 337–343.
<https://doi.org/10.1002/jso.20424>
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D., & Bray, F. (2012). *GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0 IARC CancerBase No. 11*. <https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012>
- Finch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S. A., & Colgan, T. J. (2006). Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. *Gynecologic Oncology*, 100(1), 58–64.
<https://doi.org/10.1016/j.ygyno.2005.06.065>
- Gaitskell, K., Green, J., Pirie, K., Reeves, G., & Beral, V. (2016). *Tubal ligation and ovarian cancer risk in a large cohort : Substantial variation by histological type*. 1084, 1076–1084. <https://doi.org/10.1002/ijc.29856>
- Ghosh, A., Stewart, D., & Matlashewski, G. (2004). Regulation of Human p53 Activity and Cell Localization by Alternative Splicing. *Molecular and Cellular Biology*, 24(18), 7987–7997.
<https://doi.org/10.1128/mcb.24.18.7987-7997.2004>
- Gilks, C. B. (2010). Molecular Abnormalities in Ovarian Cancer Subtypes Other

than High-Grade Serous Carcinoma. *Journal of Oncology*, 2010, 1–7.

<https://doi.org/10.1155/2010/740968>

Gong, T. T., Wu, Q.-J., Vogtmann, E., Lin, B., & Wang, Y.-L. (2013). Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. *Int J Cancer*, 132(12), 2894–2900.

Griffiths, A. J. F. (2000). tetrad - An Introduction to Genetic Analysis. In *NCBI Bookshelf*. <https://www.ncbi.nlm.nih.gov/books/NBK21878/def-item/A5444/>

Hainaut, P., & Hollstein, M. (1999). p53 and Human Cancer: The First Ten Thousand Mutations. *Advances in Cancer Research*, 77(C), 81–86.
[https://doi.org/10.1016/S0065-230X\(08\)60785-X](https://doi.org/10.1016/S0065-230X(08)60785-X)

Haldar, S., Chintapalli, J., & Croce, C. M. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. *Cancer Research*, 56(6), 1253–1255.

Haldar, S., Negrini, M., Monne, M., Sabbioni, S., & Croce, C. M. (1994). Down-Regulation of bcl-2 by p53 in Breast Cancer Cells. *Cancer Research*, 54(8), 2095–2097.

Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, 100, 57–70.

Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. *Journal of the National Cancer Institute*, 88(20), 1442–1455. <https://doi.org/10.1093/jnci/88.20.1442>

Helm, C. W., & States, J. C. (2009). Enhancing the efficacy of cisplatin in ovarian cancer treatment - Could arsenic have a role. *Journal of Ovarian Research*, 2(1), 1–7. <https://doi.org/10.1186/1757-2215-2-2>

Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. (1990). Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature*, 348, 334–336.

Holschneider, C. H., & Berek, J. S. (2000). *Ovarian Cancer : Epidemiology ,*

Biology, and. 3–10.

- Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., Ball, H., & Berek, J. S. (1994). The effect of diameter of largest residual disease on survival after primary. *Am.J.Obstet.Gynecol.*, *170*(4), 974–979.
- Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of gene for human p53 tumour antigen to band 17p13. *Nature*, *320*(6057), 84–85. <https://doi.org/10.1038/320084a0>
- Iversen, L., Fielding, S., Lidegaard, Ø., Mørch, L. S., Skovlund, C. W., & Hannaford, P. C. (2018). Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study. *BMJ (Online)*, *362*, 1–9. <https://doi.org/10.1136/bmj.k3609>
- Jäättelä, M. (1999). Escaping cell death: survival proteins in cancer. *Experimental Cell Research*, *248*, 30–43.
- Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002). Apoptosis: A Link between Cancer Genetics and Chemotherapy. *Cell*, *108*, 153–164.
- Jordan, S. J., Webb, P. M., & Green, A. C. (2005). Height, age at menarche, and risk of epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, *14*(8), 2045–2048. <https://doi.org/10.1158/1055-9965.EPI-05-0085>
- Kalloger, S. E., Köbel, M., Leung, S., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. G., & Gilks, C. B. (2011). Calculator for ovarian carcinoma subtype prediction. *Modern Pathology*, *24*(4), 512–521. <https://doi.org/10.1038/modpathol.2010.215>
- Kern, S. E. (1994). p53: Tumor suppression through control of the cell cycle. *Gastroenterology*, *106*(6), 1708–1711. [https://doi.org/10.1016/0016-5085\(94\)90431-6](https://doi.org/10.1016/0016-5085(94)90431-6)
- Kerr, J., Wyllie, A., & Currie, A. (2005). Apoptosis: A basic biological

phenomenon with wide-ranging implications in human disease. *Journal of Internal Medicine*, 258(6), 479–517. <https://doi.org/10.1111/j.1365-2796.2005.01570.x>

Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial ovarian cancer. *Journal of Experimental & Clinical Cancer Research*, 31(1), 14. <https://doi.org/10.1186/1756-9966-31-14>

Kim, D. J., Lee, M. H., Park, T. I., & Bae, H. I. (2006). Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. *Journal of Korean Medical Science*, 21(1), 81–85. <https://doi.org/10.3346/jkms.2006.21.1.81>

Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., Berkowitz, R. S., Muto, M. G., & Crum, C. P. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *American Journal of Surgical Pathology*, 31(2), 161–169. <https://doi.org/10.1097/01.pas.0000213335.40358.47>

Kobal, B., Noventa, M., Cvjeticanin, B., Barbic, M., Meglic, L., Herzog, M., Bordi, G., Vitagliano, A., Saccardi, C., & Skof, E. (2018). Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: Comparison of survivals. *Radiology and Oncology*, 52(3), 307–319. <https://doi.org/10.2478/raon-2018-0030>

Köbel, M., Huntsman, D., & Gilks, C. B. (2008). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. *Expert Reviews in Molecular Medicine*, 10(22), 1–14. <https://doi.org/10.1017/S146239940800077X>

Kurman, R. J., & Shih, I. M. (2016). The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. In *American Journal of Pathology* (Vol. 186, Issue 4, pp. 733–747). American Society for Investigative Pathology. <https://doi.org/10.1016/j.ajpath.2015.11.011>

Landis, S. H. (1999). *Cancer Statistics , 1999*.

Lauchlan, S. C. (1994). The secondary Mullerian system revisited.pdf.

International Journal of Gynecological Pathology, 13, 73–79.

Leek, R. D., Kaklamanis, L., Pezzella, F., & Gatter, K. C. (1994). Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. *British Journal of Cancer*, 69(1), 135–139. <https://doi.org/10.1038/bjc.1994.22>

Levine, A. J. (1997). p53, the Cellular Gatekeeper for Growth and Division. *Cell*, 88, 323–331.

Levine, B., Sinha, S., & Kroemer, G. (2008). BCL-2 family members. *Autophagy*, 4(5), 600–606. <https://doi.org/10.1016/j.bb.2008.05.010>

Liu, M., Peng, Y., Wang, X., Guo, Q., Shen, S., & Li, G. (2010). NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. *BMC Cancer*, 10. <https://doi.org/10.1186/1471-2407-10-160>

Loeb, K. R., & Loeb, L. A. (2000). Significance of multiple mutations in cancer. *Carcinogenesis*, 21(3), 379–385.

Lohmann, C. M., League, A. A., Clark, W. S., Lawson, D., DeRose, P. B., & Cohen, C. (2000). Bcl-2: Bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: Correlation with prognosis. *Communications in Clinical Cytometry*, 42(1), 61–66. [https://doi.org/10.1002/\(SICI\)1097-0320\(20000215\)42:1<61::AID-CYTO9>3.0.CO;2-5](https://doi.org/10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5)

Lu, Q. L., Abel, P., Foster, C. S., & Lalani, E. N. (1996). bcl-2: Role in epithelial differentiation and oncogenesis. *Human Pathology*, 27(2), 102–110. [https://doi.org/10.1016/S0046-8177\(96\)90362-7](https://doi.org/10.1016/S0046-8177(96)90362-7)

Makar, A. P., Trope, C. G., Tummers, P., Denys, H., & Vandecasteele, K. (2016). Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. *The Oncologist*, 21, 745–754.

- Mano, Y., Kikuchi, Y., Yamamoto, K., Kita, T., Hirata, J., Tode, T., Ishii, K., & Nagata, I. (1999). Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. *European Journal of Cancer*, 35(8), 1214–1219. [https://doi.org/10.1016/S0959-8049\(99\)00124-0](https://doi.org/10.1016/S0959-8049(99)00124-0)
- Mantovani, F., Collavin, L., & Del Sal, G. (2019). Mutant p53 as a guardian of the cancer cell. *Cell Death and Differentiation*, 26(2), 199–212. <https://doi.org/10.1038/s41418-018-0246-9>
- Martin, D. C. (1997). Cancer and Endometriosis: Do We Need to Be Concerned? *Seminars in Reproductive Endocrinology*, 15(3), 319–324.
- Marx, D., & Meden, H. (2001). Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer. In *Ovarian Cancer* (pp. 687–691).
- McCluggage, W. G. (2011). Morphological subtypes of ovarian carcinoma : a review with emphasis on new developments and pathogenesis. *Pathology*, 43(August), 420–432. <https://doi.org/10.1097/PAT.0b013e328348a6e7>
- McGuire, V., Hartge, P., Liao, L. M., Sinha, R., Bernstein, L., Canchola, A. J., Anderson, G. L., Stefanick, M. L., & Whittemore, A. S. (2016). Parity and oral contraceptive use in relation to ovarian cancer risk in older women. *Cancer Epidemiology Biomarkers and Prevention*, 25(7), 1059–1063. <https://doi.org/10.1158/1055-9965.EPI-16-0011>
- McGuire, W. P., & Markman, M. (2003). Primary ovarian cancer chemotherapy: Current standards of care. In *British Journal of Cancer* (Vol. 89, Issue SUPPL. 3, pp. 3–8). <https://doi.org/10.1038/sj.bjc.6601494>
- McGuire, William Patrick. (2009). Maintenance therapy for ovarian cancer: Of Helsinki and Hippocrates. *Journal of Clinical Oncology*, 27(28), 4633–4634. <https://doi.org/10.1200/JCO.2009.23.6653>
- McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. *Cold Spring Harbor Perspectives in Biology*, 5(4), 1–28. <https://doi.org/10.1101/cshperspect.a008656>

- Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006). *The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome*. *30*(2), 230–236.
- Minn, A. J., Vélez, P., Schendel, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill, M., & Thompson, C. B. (1997). Bcl-x(L) forms an ion channel in synthetic lipid membranes. *Nature*, *385*, 353–357.
- Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlabn, J. E., Yoon, H. S., Nettlesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., Ng, S.-C., & Fesik, S. W. (1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. *Nature*, *381*, 335–341.
- Nguyen, H. N., Averette, H. E., Hoskins, W., Sevin, B. □U, Penalver, M., & Steren, A. (1993). National survey of ovarian carcinoma VI: Critical assessment of Current International Federation of Gynecology and Obstetrics Staging System. *Cancer*, *72*(10), 3007–3011. [https://doi.org/10.1002/1097-0142\(19931115\)72:10<3007::AID-CNCR2820721024>3.0.CO;2-N](https://doi.org/10.1002/1097-0142(19931115)72:10<3007::AID-CNCR2820721024>3.0.CO;2-N)
- Ogston, S. A., Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1991). Adequacy of Sample Size in Health Studies. In *Biometrics* (Vol. 47, Issue 1). <https://doi.org/10.2307/2532527>
- Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986). A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study. *Cancer*, *57*(9), 1725–1730. [https://doi.org/10.1002/1097-0142\(19860501\)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J](https://doi.org/10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J)
- Paley, P. J., Swisher, E. M., Garcia, R. L., Agoff, S. N., Greer, B. E., Peters, K. L., & Goff, B. A. (2001). Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis. *Gynecologic Oncology*,

80(2), 176–180. <https://doi.org/10.1006/gyno.2000.6071>

Petros, A., Medek, A., Nettesheim, D., Kim, D., Yoon, H., Swift, K., Matayoshi, E., Oltersdorf, T., & Fesik, S. (2001). *1G5M Human BCL-2, ISOFORM 1*. RSCB Protein Data Bank. <https://doi.org/10.2210/pdb1G5M/pdb>

Piek, J. M. J., Bulten, J., van Diest, P. J., Massuger, L. F., Zweemer, R. P., & Verheijen, R. H. M. (2003). DYSPLASTIC CHANGES IN PROPHYLACTICALLY REMOVED FALLOPIAN TUBES OF WOMEN PREDISPOSED TO DEVELOP OVARIAN/FALLOPIAN TUBE CANCER. *International Journal of Gynecologic Cancer*, 13(Suppl 1), 89.3-89. <https://doi.org/10.1136/ijgc-00009577-200303001-00327>

Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., ... Perrone, F. (2011). Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. *Journal of Clinical Oncology*, 29(27), 3628–3635. <https://doi.org/10.1200/JCO.2010.33.8566>

Pistritto, G., Trisciuglio, D., Ceci, C., Alessia Garufi, & D’Orazi, G. (2016). Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. *Aging*, 8(4), 603–619. <https://doi.org/10.18632/aging.100934>

Pomel, C., Jeyarajah, A., Oram, D., Shepherd, J., Milliken, D., Dauplat, J., & Reynolds, K. (2007). Cytoreductive surgery in ovarian cancer. *Cancer Imaging*, 7(1), 210–215. <https://doi.org/10.1102/1470-7330.2007.0030>

Raja, F. A., Chopra, N., & Ledermann, J. A. (2012). symposium article Optimal first-line treatment in ovarian cancer. *Educational Book of the 37th ESMO Congress, Vienna, Austria, 28 September – 2 October 2012*, 23(Supplement 10), x118–x127. <https://doi.org/10.1093/annonc/mds315>

- Reece, J. B., Urry, L. A., Cain, M. L., Campbell, N. A., Minorsky, P. V, Jackson, R. B., & Wasserman, S. A. (2012). *Biology* (10th ed.). Pearson Publishing.
- Reed, J. C. (1995). Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. *Oncology*, 7, 541–546.
- Reed, J. C. (1997). Double identity for proteins of the Bcl-2 family. *Nature*, 387(6635), 773–776. <https://doi.org/10.1038/42867>
- Reid, B. M., Permut, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. *Cancer Biology and Medicine*, 14(1), 9–32. <https://doi.org/10.20892/j.issn.2095-3941.2016.0084>
- Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M., & Reed, J. C. (1997). Channel formation by antiapoptotic protein Bcl-2. *Proceedings of the National Academy of Sciences of the United States of America*, 94(10), 5113–5118. <https://doi.org/10.1073/pnas.94.10.5113>
- Schuyer, M., Van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. M. J. J. (2001). Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: A multifactorial analysis of TP53, p21, BAX and BCL-2. *British Journal of Cancer*, 85(9), 1359–1367. <https://doi.org/10.1054/bjoc.2001.2101>
- Seidman, Jeffery D, Cho, K. R., Ronnet, B. M., & Kurman, R. J. (2002). Surface Epithelial Tumors of the Ovary. In R. J. Kurman, L. H. Ellenson, & B. M. Ronnett (Eds.), *Blaustein's Pathology of the Female Genital Tract* (6th ed., pp. 679–784). Springer.
- Seidman, Jeffrey D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2004). The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin. *International Journal of Gynecological Pathology*, 23(1), 41–44. <https://doi.org/10.1097/01.pgp.0000101080.35393.16>
- Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S.,

- Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., Pockaj, B. A., Laman, S. D., Pittelkow, M. R., & Markovic, S. N. (2008). Malignant melanoma in the 21st century: The emerging molecular landscape. *Mayo Clinic Proceedings*, 83(7), 825–846. <https://doi.org/10.4065/83.7.825>
- Shaw, P. A., Rouzbahman, M., Pizer, E. S., Pintilie, M., & Begley, H. (2009). Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. *Modern Pathology*, 22(9), 1133–1138. <https://doi.org/10.1038/modpathol.2009.89>
- Sherman, M. E., Lee, J. S., Burks, R. T., Struewing, J. P., Kurman, R. J., & Hartge, P. (1999). Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. *International Journal of Gynecological Pathology*, 18, 151–157.
- Shih, I. M., & Kurman, R. J. (2004). Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. *American Journal of Pathology*, 164(5), 1511–1518. [https://doi.org/10.1016/S0002-9440\(10\)63708-X](https://doi.org/10.1016/S0002-9440(10)63708-X)
- Shimizu, Y., Kamoi, S., Amada, S., Hasumi, K., Akiyama, F., & Silverberg, S. G. (1998). Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. *Gynecologic Oncology*, 70(1), 2–12. <https://doi.org/10.1006/gyno.1998.5051>
- Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., & Veronesi, U. (1994). The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in LymphNode-Negative Breast Cancer Patients. *Journal of the National Cancer Institute*, 86(7), 499–504.
- Singh, N., Gilks, C. B., Wilkinson, N., & McCluggage, W. G. (2015). The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous

- carcinoma and why assignment of primary site matters. In *Pathology* (Vol. 47, Issue 5, pp. 423–431). <https://doi.org/10.1097/PAT.0000000000000291>
- Skírnisdóttir, I., & Seidal, T. (2012). The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment. *Oncology Reports*, 27(3), 741–747. <https://doi.org/10.3892/or.2011.1578>
- Skirnisdóttir, I., Sorbe, B., & Seidal, T. (2001). P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. *International Journal of Gynecological Cancer*, 11(2), 147–158. <https://doi.org/10.1046/j.1525-1438.2001.01003.x>
- Solomon, E., Martin, C., Martin, D. W., & Berg, L. R. (2008). *Biology* (8th ed.). Thomson Brooks/Cole.
- Tapia, G., & Diaz-Padilla, I. (2013). Molecular Mechanisms of Platinum Resistance in Ovarian Cancer. In *Ovarian Cancer - A Clinical and Translational Update* (pp. 2015–2223). <https://www.intechopen.com/books/ovarian-cancer-a-clinical-and-translational-update/molecular-mechanisms-of-platinum-resistance-in-ovarian-cancer>
- Tas, F., Duranyildiz, D., Oguz, H., Camlica, H., Yasasever, V., & Topuz, E. (2006). The value of serum bcl-2 levels in advanced epithelial ovarian cancer. *Medical Oncology*, 23(2), 213–217. <https://doi.org/10.1385/MO:23:2:213>
- Tavassoli, F., & Devilee, P. (2003). *Pathology and Genetics: Tumours of the Breast and Female Genital Organs*. IARC Press.
- Tchelebi, L., Ashamalla, H., & Graves, P. R. (2014). Mutant p53 and MDM2 in Cancer. *Sub-Cellular Biochemistry*, 85, 133–159. <https://doi.org/10.1007/978-94-017-9211-0>
- Ueland, F. (2017). A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come. *Diagnostics*, 7(1), 14.

<https://doi.org/10.3390/diagnostics7010014>

- Vaux, D. L., Cory, S., & Adams, J. M. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. In *Nature* (Vol. 335, Issue 6189, pp. 440–442). <https://doi.org/10.1038/335440a0>
- Veras, E., Mao, T. L., Ayhan, A., Ueda, S., Lai, H., Hayran, M., Shih, I. M., & Kurman, R. J. (2009). Cystic and adenofibromatous clear cell carcinomas of the ovary: Distinctive tumors that differ in their pathogenesis and behavior: A clinicopathologic analysis of 122 cases. *American Journal of Surgical Pathology*, 33(6), 844–853. <https://doi.org/10.1097/PAS.0b013e31819c4271>
- Verma, P., Chierzi, S., Codd, A. M., Campbell, D. S., Meyer, R. L., Holt, C. E., & Fawcett, J. W. (2005). Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. *Journal of Neuroscience*, 25(2), 331–342. <https://doi.org/10.1523/JNEUROSCI.3073-04.2005>
- Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. *Nature*, 408, 307–310.
- Wong, K. K., Izaguirre, D. I., Kwan, S. Y., King, E. R., Deavers, M. T., Sood, A. K., Mok, S. C., & Gershenson, D. M. (2013). Poor survival with wild-type TP53 ovarian cancer? *Gynecologic Oncology*, 130(3), 565–569. <https://doi.org/10.1016/j.ygyno.2013.06.016>
- Wong, R. S. Y. (2011). Apoptosis in cancer: From pathogenesis to treatment. *Journal of Experimental and Clinical Cancer Research*, 30(1), 87. <https://doi.org/10.1186/1756-9966-30-87>
- Wood, M. E., Garber, J. E., Isaacs, C., Masood, S., Bedrosian, I., Tung, N., Chun, J., Schnabel, F. R., & Arun, B. K. (2019). Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. *Breast Journal*, 25(4), 575–577. <https://doi.org/10.1111/tbj.13292>
- Woodward, E. R., Sleightholme, H. V., Considine, A. M., Williamson, S., McHugo, J. M., & Cruger, D. G. (2007). Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population

risk women is ineffective. *BJOG: An International Journal of Obstetrics and Gynaecology*, 114(12), 1500–1509. <https://doi.org/10.1111/j.1471-0528.2007.01499.x>

Xiao, J., Zhou, Y., & Zhu, W. (2015). Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma. *International Journal of Clinical and Experimental Pathology*, 8(6), 6458–6465.

Xu, X., Deng, F., Lv, M., Ren, B., Guo, W., & Chen, X. (2016). Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. *Journal of Ovarian Research*, 9(1), 1–8. <https://doi.org/10.1186/s13048-016-0294-z>

Yoshikawa, K., Fukuda, T., Uemura, R., Matsubara, H., Wada, T., Kawanishi, M., Tasaka, R., Kasai, M., Hashiguchi, Y., Ichimura, T., Yasui, T., & Sumi, T. (2018). Age-related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer. *Molecular and Clinical Oncology*. <https://doi.org/10.3892/mco.2018.1668>

Zhao, W. J., & Wang, K. (2013). NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. *International Journal of Oncology*, 42(6), 2060–2068. <https://doi.org/10.3892/ijo.2013.1886>